We use cookies to ensure that we give you the best experience on our website.
When you use our platform without an account you need to read and accept the
Terms of Service, Data Policy and Disclaimer(s).
Biotechnology
Healthcare
US
West Conshohocken
IR
SEC
ISIN
Market Cap.:5.3 B
M
Market Capitalization - Sizes
Here you can see how we classify a market capitalization.
XS
< 100 Mil.
S
> 100 Mil.
M
> 1 Bil.
L
> 10 Bil.
XL
> 100 Bil.
P/E:-9.48
x50.11Industry Within Country Benchmark (IWCB)
The multiplier shows you the relation between a reported metric, e.g. Earnings Per Share (EPS)
and the μ EPS value of the corporate's industry.
We exclude other countries from the average calculation in order to
take into account the specific economic and regulatory conditions in that country.
Concrete for "Biotechnology" in United States
EPS: -2.1086,
P/E: 50.1108
EPS:-25.55
x
0.08
Industry Within Country Benchmark (IWCB)
The multiplier shows you the relation between a reported metric, e.g. Earnings Per Share (EPS)
and the μ EPS value of the corporate's industry.
We exclude other countries from the average calculation in order to
take into account the specific economic and regulatory conditions in that country.
Concrete for Biotechnology in United States
EPS: -2.1086,
P/E: 50.1108
Earnings Call
1 month, 2 weeks from now
Dividend Waiting Time
We compute the average time difference between dividend payments
and assign an indicator that holds a general grade for that frequency.
Low
Average time between dividend payments is less than 3 months.
Neutral
Average time between dividend payments is between 3 to 6 months.
High
Average time between dividend payments is more than 6 months.
n.A.
Latest Dividends History
Each bar represents a dividend payment made within the last 12 months, with the bar's height relative to the maximum dividend paid within that timeframe.
See all Dividends.
Yield
Payout
Volume LevelVolume Deviation Rating System (VDRS)
We compare the 15-minute delayed volume to the average volume and grade the percentual deviation.
High
Deviation >= 20%
Moderate High
Deviation between 10% to 20%
Moderate
Deviation between -10% to 10%
Moderate Low
Deviation between -20% to -10%
Low
Deviation between <= -20%
μ 281,517
287,395
Moderate Low
Performance Ranks (Intraday)A system to benchmark MDGL's relative intraday performance.
Each star represents "20% have worse results", e.g. 4/5 stars symbolize that the corporate had a better result than 80% of the benchmark compotion.
United States:
177th
out of
2160
Healthcare:
53rd
out of
792
Biotechnology:
24th
out of
227
Peer Group:
1st
out of
4
About
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid …
About
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid …
Berkshire Hathaway
Profile, Qualitative, Financials ...
Overview
Royal Bank Of Canada
Valuation Models & History
Financials
Alphabet Inc. - Competitors
SNAP, TWLO, PINS, META ...
Comp.
Amazon.com, Inc.
Risks/AI
NLP Analyzed Risk Factors, AI Arguments
Apple Inc. vs. Peers & Industry Benchmarks
Benchmarks Industry
Peter Lynch Screener
Strategy